Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Roginolisib |
| Trade Name | |
| Synonyms | IOA 244|IOA-244|IOA244 |
| Drug Descriptions |
Roginolisib is a selective PIK3CD inhibitor, which potentially modulates the tumor microenvironment, leading to an antitumor immune response, and inhibits cell proliferation (PMID: 37066023). |
| DrugClasses | PIK3CD inhibitor 27 |
| CAS Registry Number | 1305267-37-1 |
| NCIT ID | C203162 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Docetaxel + Dostarlimab-gxly + Roginolisib | Docetaxel Dostarlimab-gxly Roginolisib | 0 | 1 |
| Dostarlimab-gxly + Roginolisib | Dostarlimab-gxly Roginolisib | 0 | 1 |
| Rituximab + Roginolisib + Venetoclax | Rituximab Roginolisib Venetoclax | 0 | 1 |
| Roginolisib | Roginolisib | 0 | 3 |
| Roginolisib + Tebentafusp | Roginolisib Tebentafusp | 0 | 1 |
| Roginolisib + unspecified PD-1 antibody | Roginolisib unspecified PD-1 antibody | 0 | 0 |